Review of pneumococcal conjugate vaccine in adults: implications on clinical development

被引:32
作者
Abraham-Van Parijs, B
机构
[1] GlaxoSmithKline, Clin Dev & Med Affairs N America, Antiinfect, Collegeville, PA 19460 USA
[2] Wyeth Pharmaceut, Global Med Affairs Vaccines, Collegeville, PA 19426 USA
关键词
pneumococcal; conjugate vaccine; adults;
D O I
10.1016/j.vaccine.2004.01.029
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A literature review was conducted to determine if pneumococcal conjugate vaccines administered to healthy and immunocompromised adults, in comparison with the known efficacy in children, showed immunogenicity. Fifteen publications were retrieved. Clinical studies had been conducted using vaccines from different manufacturers, in different populations, using varied methodologies. No clear evidence of the superiority of the conjugate vaccine over the currently licensed polysaccharide vaccine emerged. Possible reasons for the lack of superiority and its implications on vaccine development are discussed. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1362 / 1371
页数:10
相关论文
共 39 条
[1]   Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: Results from a randomized trial [J].
Ahmed, F ;
Steinhoff, MC ;
RodriguezBarradas, MC ;
Hamilton, RG ;
Musher, DM ;
Nelson, KE .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (01) :83-90
[2]  
[Anonymous], 1997, MMWR Recomm Rep, V46, P1
[3]   Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence [J].
Ball, P ;
Baquero, F ;
Cars, O ;
File, T ;
Garau, J ;
Klugman, K ;
Low, DE ;
Rubinstein, E ;
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (01) :31-40
[4]   COMMUNITY-ACQUIRED PNEUMONIA [J].
BARTLETT, JG ;
MUNDY, LM .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (24) :1618-1624
[5]  
Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954
[6]   Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia [J].
Black, SB ;
Shinefield, HR ;
Ling, S ;
Hansen, J ;
Fireman, B ;
Spring, D ;
Noyes, J ;
Lewis, E ;
Ray, P ;
Lee, J ;
Hackell, J .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (09) :810-815
[7]  
*BRIT THOR SOC, 2001, THORAX S4, V56
[8]   Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease [J].
Chan, CY ;
Molrine, DC ;
George, S ;
Tarbell, NJ ;
Mauch, P ;
Diller, L ;
Shamberger, RC ;
Phillips, NR ;
Goorin, A ;
Ambrosino, DM .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (01) :256-258
[9]   Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults [J].
Feikin, DR ;
Elie, CM ;
Goetz, MB ;
Lennox, JL ;
Carlone, GM ;
Romero-Steiner, S ;
Holder, PF ;
O'Brien, WA ;
Whitney, CG ;
Butler, JC ;
Breiman, RF .
VACCINE, 2001, 20 (3-4) :545-553
[10]  
GAILLAT J, 1985, REV EPIDEMIOL SANTE, V33, P437